Shivam Singh

PharmaShots Newsroom press release graphic

Philips introduces Advanced Image Insights for advanced visualization and AI orchestration

November 19, 2026 09:00 ET  | Source: Philips International B.V. Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced Philips Advanced Image Insights on HealthSuite [1], a cloud-based solution combining Philips advanced visualization applications with centralized management and orchestration of third-party AI applications for imaging. Connected

PharmaShots Newsroom press release graphic

Adagene Announces First Patient Dosed in Phase 1 Study of ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager

November 19, 2026 07:00 ET  | Source: Adagene Inc. SAN DIEGO, Nov. 19, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that the first patient has been dosed in a first-in-human Phase 1 study of ADG138, a double-masked

EBI Reaches Key Milestone with First Patient Enrolled in Phase III EasyBoost Trial of EA-230, a Potential First-in-Class Medicine to Accelerate Recovery After Cardiac Surgery

November 19, 2026 06:10 ET  | Source: Exponential Biotherapies, Inc. THE HAGUE, the Netherlands, Nov. 19, 2026 (GLOBE NEWSWIRE) — EBI NL B.V. (EBI NL), a Dutch Group company of Exponential Biotherapies, Inc. (EBI), today announced that the first patient has been enrolled in the EasyBoost trial (NCT07357675), a multicentre, multinational, randomised, double-blind, placebo-controlled Phase

PharmaShots Newsroom press release graphic

Adagene and City of Hope Open Clinical Trial to Test New Therapy for Patients with Hard-to-Treat Colorectal Cancer

November 17, 2026 08:00 ET  | Source: Adagene Inc. SAN DIEGO and LOS ANGELES, Nov. 17, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, and City of Hope, one of the largest and most advanced cancer research and treatment organizations

SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine…

SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid Leukemia

November 17, 2026 07:00 ET  | Source: SELLAS Life Sciences Group, Inc. NEW YORK, Nov. 17, 2026 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced positive topline results

PharmaShots Newsroom press release graphic

AGC Biologics Welcomes Multiple Cell Therapy Projects to New Yokohama Site

November 16, 2026 19:00 ET  | Source: AGC Biologics, Inc. YOKOHAMA, Japan, Nov. 16, 2026 (GLOBE NEWSWIRE) — While there is growing interest and momentum for cell and gene therapy development in Japan, there are a limited number of CDMOs with the institutional knowledge, manufacturing prowess, talent development, and international network. To advance their projects

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative…

U.S. FDA Approves IGALMI® as First At-Home Acute Treatment for Agitation Associated with Schizophrenia, Schizoaffective Disorder, or Bipolar I or II Disorder in Adults

November 16, 2026 08:00 ET  | Source: Teva Pharmaceuticals PARSIPPANY, N.J., Nov. 16, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the U.S. Food and Drug Administration (FDA) approval of IGALMI (dexmedetomidine) sublingual film for at-home use. With this approval, IGALMI becomes the

Cyclarity Therapeutics Receives FDA Investigational New Drug Clearance for UDP-003 to expand Atherosclerosis Clinical…

Cyclarity Therapeutics Receives FDA Investigational New Drug Clearance for UDP-003 to expand Atherosclerosis Clinical Development Program into the United States

November 13, 2026 01:32 ET  | Source: Cyclarity Therapeutics NOVATO, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) — Cyclarity Therapeutics, Inc., a clinical-stage biotechnology company developing cyclodextrin therapeutics to reverse atherosclerotic cardiovascular diseases and metabolic diseases of aging, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application

Evosep Appoints Scientia Life Technologies as Distributor in India

Evosep Appoints Scientia Life Technologies as Distributor in India

November 12, 2026 03:00 ET  | Source: Evosep Partnership gives India’s proteomics community more direct access to Evosep solutions, local expertise and support BHUBANESWAR, India, Nov. 12, 2026 (GLOBE NEWSWIRE) — Evosep today announced the appointment of Scientia Life Technologies LLP as its distributor in India. The agreement was signed during the Education Day of

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative…

Teva Shares Innovative Pipeline Updates and Unveils Path to Future Growth at R&D Day, Targeting $6–7 Billion in Innovative Medicines Revenue by 2030

November 11, 2026 07:30 ET  | Source: Teva Pharmaceutical Industries Ltd The Company has more than doubled revenue from innovative medicines since launching Pivot to Growth in 2023, demonstrating sustained execution and the growing strength of its high-velocity biopharma model A live webcast of the event and presentation materials will be available on Teva’s Investor Relations

PharmaShots Newsroom press release graphic

Philips launches HyperVue Integrated System in the U.S., bringing advanced coronary imaging and physiology into the cathlab

October 30, 2026 16:00 ET  | Source: Royal Philips Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced U.S. commercial availability of the HyperVue Integrated System1, a new single room-based configuration of its HyperVue Imaging System for DeepOCT+NIRS imaging and X1-FFR physiology assessment. It is designed

PharmaShots Newsroom press release graphic

Boehringer Ingelheim registers Phase III trial investigating verducatib in COPD

October 30, 2026 09:37 ET  | Source: Boehringer Ingelheim Ingelheim, Germany and Ridgefield, Conn., U.S. – Boehringer Ingelheim today announced the registration of the Phase III AIRWARD™ trial evaluating its investigational oral therapy verducatib as a treatment option targeting DPP1 in adults with COPD; the trial was published on ClinicalTrials.gov (NCTXXXXXX).1 The trial will evaluate

PharmaShots Newsroom press release graphic

Asia-Pacific is rapidly gaining importance as a major pillar in global life science innovation

October 30, 2026 05:07 ET  | Source: Boehringer Ingelheim Seoul, Korea – Boehringer Ingelheim today highlighted Asia-Pacific’s increasing importance in global life science innovation. Speaking at the Asia-Pacific Conference of German Business (APK) 2026 in Seoul, Shashank Deshpande, Boehringer Ingelheim Chairman of the Board of Managing Directors, said that “Asia-Pacific is rapidly gaining importance as

Junshi Biosciences Announces Strategic Collaboration with Antengene to Evaluate Combination Therapy with JS207 (PD-1/VEGF…

Junshi Biosciences Announces the Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS207 in Combination with JS007 for the First-Line Treatment of Advanced Hepatocellular Carcinoma

October 29, 2026 07:04 ET  | Source: Junshi Biosciences SHANGHAI, Oct. 29, 2026 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the first patient dosing has been completed in a multi-center, randomized,

PharmaShots Newsroom press release graphic

Philips launches UniGuide 3D Live Guidance, bringing CT planning into live procedures and extending the capabilities of its Azurion image-guided therapy platform

October 29, 2026 05:00 ET  | Source: Royal Philips October 29, 2026 New CE-marked solution leverages the industry-leading Philips Azurion platform to integrate CT-derived insights and treatment planning directly into the procedural workflow, helping physicians make informed decisions during treatment.Amsterdam, the Netherlands –Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and

Scroll to Top